NCT04778527 is a NA clinical trial of Dual Prevention Pill in HIV Infections, sponsored by Population Council.

Who is sponsoring NCT04778527?

NCT04778527 is sponsored by Population Council.

What drugs are being tested in NCT04778527?

Interventions in NCT04778527: Dual Prevention Pill, PrEP tablet and a COC as two separate tablets.

What condition does NCT04778527 study?

NCT04778527 studies HIV Infections.

Is NCT04778527 still recruiting?

NCT04778527 is currently status unknown. Last updated 6 February 2024.

Last reviewed 2024-02-06 · How we verify

NCT04778527

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Crossover Adherence and Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention

Status unknown NA Last updated 6 February 2024

What this trial tests

NA trial testing Dual Prevention Pill in HIV Infections in 96 participants. Status unknown.

Timeline

13 September 2022

Primary endpoint
31 January 2024

31 January 2024

Quick facts

Lead sponsor	Population Council
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	96
Start date	13 September 2022
Primary completion	31 January 2024
Estimated completion	31 January 2024
Sites	1 location across South Africa

Drugs / interventions tested

Dual Prevention Pill — full drug profile →
PrEP tablet and a COC as two separate tablets — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Population Council

Who can join

Adults 16 to 40, female only, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, crossover study to compare adherence, preference and acceptability of an over-encapsulated dual prevention pill (DPP capsule) containing oral pre-exposure prophylaxis (PrEP) and a combined oral contraceptive (COC) versus two separate tablets (PrEP and COC) among women at risk of HIV and unintended pregnancy in Johannesburg, South Africa

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in
Friedland BA, Mgodi NM, Palanee-Phillips T, Mathur S, et al · · 2024 · cited 4× · PMID 38479746 · DOI 10.1136/bmjopen-2023-075381
Adherence, Preference, and Acceptability of an Overencapsulated Dual Prevention Pill for HIV and Pregnancy Prevention Among Women in Johannesburg, South Africa.
Ndlovu N, Plagianos M, Palanee-Phillips T, Reddy K, et al · · 2026 · PMID 41526807 · DOI 10.1097/qai.0000000000003780
Factors associated with women’s preference for an over-encapsulated Dual Prevention Pill: Findings from two clinical crossover trials among women in South Africa and Zimbabwe
Mathur S, Plagianos M, Friedland B, Bruce I, et al · · 2025 · DOI 10.21203/rs.3.rs-6683281/v1

Verify or expand the search:

Other trials of Dual Prevention Pill

Trials testing the same drug.

NCT04778514 — A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention · NA · completed

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Population Council trials

Trials by the same sponsor.

NCT07039591 — Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlan · EARLY_PHASE1 · recruiting
NCT04778514 — A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention · NA · completed
NCT05644886 — Pilot Study on Engaging Family Physicians in Family Planning in Pakistan · NA · unknown
NCT05128136 — A Crossover Study Evaluating 3 Non-medicated Silicone IVRs · NA · completed
NCT02875119 — Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04778527 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Population Council
Last refreshed: 6 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04778527.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing